The "three controls" on drug prices in Guangdong Province have been implemented for five years, and have been abolished today!

Source: Medical cloud information 2015-08-26 notice on Abolishing the "three controls" management of drug prices was posted on the official website of Guangdong Provincial Development and Reform Commission The so-called "three controls" refers to the "three controls" management of controlling the highest retail price, the actual supply price and the price difference rate of circulation of drugs under the guidance of the government At the end of November 2009, the national development and Reform Commission, the Ministry of health and the Ministry of human resources and Social Security jointly issued the opinions on the reform of the price formation mechanism of drugs and medical services, calling for the upper limit control of the price difference rate (amount) in drug circulation In order to further regulate the circulation of drugs, Guangdong, as the only pilot province of the national drug price reform, plans to take the lead in launching the "three control" management mode of drug prices nationwide In August 2010, the price bureau of Guangdong Province issued the notice on the implementation of "three controls" management on drug prices, and decided to implement "three controls" for two years from September 1, 2010 In fact, it has been implemented so far The first control: control the maximum retail price, which is well understood, is to set a price ceiling to control; the second control: control the actual supply price For the government priced drugs sold in the Guangdong market, before they are put on the market, the production and operation enterprises It is necessary to report the supply price (including ex factory or port price) of the drug sold in Guangdong market to the competent price department The supply price shall be determined by the enterprise itself, but shall not exceed the maximum retail price of drugs, and shall not be changed at will within the prescribed time limit after filing Third control: control the price difference rate of circulation According to the actual situation of Guangdong Province, the drug circulation difference rate is formulated uniformly, including distribution rate and differential difference rate That is to say, with the decrease of drug amount, the circulation difference rate shows an increasing trend The purpose of this design is said to be to encourage enterprises to produce low-cost drugs, suppress high-cost drugs, guide medical institutions to reduce the use of high-cost drugs, encourage the use of low-cost drugs, and benefit the people But it doesn't work From the upper limit of price to the price difference control in the process of ex factory report and re circulation, it seems that the price of drugs will be adjusted in exchange, the circulation process will be compressed and the price of drugs will be restrained However, during the formulation and implementation period of the "three controls" policy, the pricing source of drug prices lies in the national development and Reform Commission The drug companies with the highest retail price are generally difficult to reach, and the actual price mainly depends on the price Circulation link, no matter you are a link or n links, since the maximum retail price has been set, what is the use of compression link? In fact, the distribution rate or differential price difference rate in Guangdong is far lower than the standard of "three controls", and the three controls policy is equivalent to nothing What's more, the "three controls" are aimed at the varieties priced by the government, that is, the commonly known medical insurance varieties and the varieties under the control of Guangdong Province (some non-medical insurance) In terms of the number of drugs, the proportion is less than 30%, and nearly 70% of the non-medical insurance varieties are not included in the "three controls" The actual impact on enterprises is that they need to report to Guangdong market for sales, especially in the bidding process This reporting system brings a lot of reporting risks to the manufacturers of base price sales If it is reported at the base price, it means that the price system is completely crushed by the enterprise itself, and it is completely a behavior of self financing No enterprise will do so If it is to report, it is necessary to provide a VAT invoice for self certification of factory price every quarter according to the specific implementation details of "three controls" This is not available for many enterprises that have not prepared or engaged in the high-tech mode before But from the bidding of basic drugs in 2011 to the new registration rules of drug trade in 2013, it must be reported So, the eight immortals of pharmaceutical companies across the sea show their own magic power As for the way and problems, you know! Such a policy is similar to the "two vote system" in Fujian, aiming to reduce the price of drugs in the middle link However, there are Countermeasures under the policy, and the good original intention has not been reflected The national development and Reform Commission cut prices 32 times in a row, but the price of drugs failed to decline significantly To prove that this road is impassable, we need to find another way, "three controls" is one of the ways However, price management still relies on layer by layer control Instead, it controls many disordered images, which can not cure the symptoms On June 1 this year, the national drug price reform cancelled the highest retail price of most drugs priced by the government, and the "three controls" obviously belonged to one of the adjusted policies For the manufacturers who come to Guangdong to sell drugs, it is not necessary to apply for the above-mentioned registration But the fact that the government does not regulate here does not mean that there is less regulation or self-regulation Pharmaceutical companies should actively adjust their marketing model to meet the needs of future regulation and market You can't take chances with the future.